Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

Contact Us

Search

pediatric rare diseases

Rare Disease news

Rare Diseases Weekly News - July 3rd 2025

🧬 This Week in Rare Diseases: First MAS Approval, AI-Powered Diagnostics,…

Rare Disease news

Rare Diseases Weekly News - June 26th 2025

🧬 This Week in Rare Diseases: Genome Testing, First Approvals, Global…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B

Tags

advanced therapies AI in dermatology argenx Biohacking bioinformatics Bispecific antibody therapy Canada National Strategy for Drugs for Rare Diseases cancer Celea Therapeutics clinical strategy corporate venture capital Diffuse large B-cell lymphoma EAS 2025 Elranatamab ESMO 2021 Etiprimal gene editing gene therapy approval hematology HSA JACC Advances JPM 2026 Ketamine Microbiome analysis molecular design Mucosal immunity myocardial infarction Myocarditis NeuraLight NFTs in healthcare NIHR Southampton non viral vectors noom oncology trials pharma Pharma pipeline analysis prevention Recessive dystrophic epidermolysis bullosa Respiree retinal ai Sema4 skin conditions Tessera Therapeutics Teva Pharmaceuticals Vertex Pharmaceuticals

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B

TAGS

advanced therapies AI in dermatology argenx Biohacking bioinformatics Bispecific antibody therapy Canada National Strategy for Drugs for Rare Diseases cancer Celea Therapeutics clinical strategy corporate venture capital Diffuse large B-cell lymphoma EAS 2025 Elranatamab ESMO 2021 Etiprimal gene editing gene therapy approval hematology HSA JACC Advances JPM 2026 Ketamine Microbiome analysis molecular design Mucosal immunity myocardial infarction Myocarditis NeuraLight NFTs in healthcare NIHR Southampton non viral vectors noom oncology trials pharma Pharma pipeline analysis prevention Recessive dystrophic epidermolysis bullosa Respiree retinal ai Sema4 skin conditions Tessera Therapeutics Teva Pharmaceuticals Vertex Pharmaceuticals

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

© 2025 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy